The far left’s demonization of pharmaceutical drug pricing practices generated anxiety among shareholders in the event of a Clinton victory in the US presidential election. Nonetheless, several drug companies skyrocketed out of the gate, largely with Mylan among the chief notable gainer after coming under fire after the EpiPen controversy.Among other chief gainers:TEVA -- +6%PFE -- +5%ABBV -- +4%AGN -- +4%AMGN -- +4%CELG -- +3%REGN -- +3%NVS -- +3%GILD -- +2%MRK -- +2%